The World Health Organisation has recently recommended that: "HbA 1c can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardized to criteria aligned to the international reference values, and there are no conditions present that preclude its accurate measurement." In November 2012 a consensus statement on the approach was published on behalf of the Department of Health Advisory Committee on Diabetes Mellitus on the use of HbA 1c diagnostically within the UK. Details of the envisaged mode of application are given in the Appendix. This will lead to a significant cost pressure for Clinical Biochemistry budgets in Scotland (conservatively estimated at £600k per annum) and provide significant operational pressures in delivery of increased HbA 1c workloads. The adoption of this approach across Scotland will not only have significant resource implications for SCBMDN laboratories, but may give rise to potential clinical governance issues if not managed appropriately in a coordinated manner. There is a need for health boards to develop an initial position on this development while all stakeholders consider the implications for diagnosis and management of diabetes in Scotland and secure the resources to deliver the approach safely and effectively.
Background
The biochemical diagnosis of diabetes mellitus has relied in the past on measurement of blood glucose and also the use of oral glucose tolerance testing. Glucose measurements are highly automated in Scottish laboratories and can be delivered at a cost of circa 6 pence per test. To monitor diabetic control glycated haemoglobin (Haemoglobin A 1c ) is measured, usually on standalone chromatographic systems that are comparatively much more labour intensive at a cost ranging from £1.20 to £1.50 per test. These costs relates to reagents and costs of instrumentation only.
World Health Organisation (WHO) identified the approach that underpins current practice employing glucose measurements. However in 2011 WHO concluded that HbA 1c could be used diagnostically as a diagnostic test which has subsequently led to the publication of an expert position paper (consensus statement) from the Department of Health Advisory Committee on Diabetes Mellitus on the use of HbA 1c diagnostically within the UK. In the summary of that paper the following is stated: -"This new method of diagnosing diabetes will identify a different cohort as having diabetes than is currently being diagnosed; but the process of investigation that does not require a fasting sample makes investigation easier, allowing more people to be investigated". This statement clearly identifies that an increasing workload might result from adoption of the new diagnostic approach and it is also clear that there are degrees of complexity in its application as a consequence of the number of situations in which HbA 1c cannot be applied (see appendix). The situations in which it is suggested that HbA 1C should be used to effectively screen for diabetes is also potentially very large. 1 Primary care physicians are keen on the approach to diagnosis, since it removes the requirement for fasting patients, and reduces the need for oral glucose tolerance testing. However it is clear that they will require significant preparative education requiring not only wide dissemination of the flow diagrams contained within the consensus statement, but also appropriate narrative, if the test is to be used appropriately. 2 SCBMDN anticipates that adoption of the consensus statement recommendations will lead to a significant increase in laboratory workload for HbA 1c . A conservative estimate is that this will exceed 100% (according to anecdotal evidence from other European labs and early adopters in the UK). This will have a significant impact on analytical capacity and cost. In 2011, 434,000 HbA 1c tests were performed by Scottish biochemistry laboratories (data from Keele National Pathology Benchmarking Service and data collected by SCBMDN). At a cost of £1.20-£1.50 a test, the cost of the anticipated workload increase to Scottish laboratories could be in excess of £600,000.
Assessment
This approach to diagnosis of diabetes represents a significant change to current practice and needs to be managed accordingly. There is recognition that a different population of diabetics will be identified, and that there will consequently still be a need for the conventional approach to diagnosis in a range of patients. It is also recognised that ease of testing a large target population will all lead to increased workloads for laboratories both in terms of initial diagnosis and follow up of patients. There will be a need for education of users requiring close co-operation of the various stakeholders. This might be better achieved by a nationally co-ordinated approach that is linked to delivery of capacity in terms of diagnostics and in managing the impacts at the point of care around.
There will be significant cost pressures on laboratory budgets when this diagnostic approach is adopted. It is recognised that across the whole Healthcare economy that this development will potentially be accompanied by reductions in the costs of administering oral glucose tolerance tests (OGTT) and of repeated patient appointments (to ensure provision of a fasting sample), which in turn leads to a better experience for patients. Savings accrued however will be primarily outside of the laboratory and not accrue in laboratory budgets given that the relative costs of HbA 1c testing is so much more than that for glucose (£1.20 versus £0.06 per reportable test). The impacts on laboratories serving the biggest populations will be considerable financially and will prove particularly challenging in terms of delivery of the analytical capacity given current technologies used. This may require laboratories to reconfigure their service provision to enable delivery of the increased volume of testing. There are likely to be impacts on reagent costs, equipment requirements and staffing.
There will be a requirement for active management of demand for HbA 1c , to ensure that the consensus algorithms are followed appropriately. There is not only potential here for significant volume growth, but also for significant rise in inappropriate use in contexts where the testing is unreliable and therefore unsafe. The impacts on diabetes clinics and other diabetes related resources needs to be identified and scoped.
To ensure successful adoption and benefits realisation of a safe transition to HbA 1c measurement for diagnosis of diabetes mellitus, the SCBMDN believes that there is a need for provision of appropriate guidance on interpretation for users, education relating specifically to clinical conditions which preclude the use of HbA 1c as a diagnostic test, development of demand management strategies, and delivery of appropriate resources to laboratories to enable the service delivery. The laboratory services will need to give some consideration as to methodological requirements and address any differences in approach across Scottish Health Boards that might complicate the move.
There is a danger that this diagnostic approach to diabetes might be introduced by stealth as GPs and patients become increasingly aware of it following the publication of the consensus statement. It is therefore a matter of some urgency that health boards develop a position on its introduction to enable a controlled, safe and appropriately funded deployment. 
Recommendations

